-
Therefore, these findings demonstrate not only that pregnancy has no adverse effects on the rate of MS relapses, but it also provides further evidence of the beneficial effects both of pregnancy and the postpartum period, over the long term, indicating a
-
"We have shown for the first time that immediate treatment after a first clinical demyelinating event suggestive of MS can reduce the early neurological damage, which may ultimately delay the development of the debilitating sequelae that characterize adv
-
Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potentially more effective way of treating the progressive neurological disease.
-
To identify clinical and demographic factors associated with long-term disability in patients with relapsing-remitting multiple sclerosis.
-
The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
-
The study, to be published in the Dec. 3 advance online edition of Nature Immunology, lays the groundwork for a way to determine when a relapse is about to occur, and could eventually lead to a treatment to prevent relapses.
-
The phase IIb clinical study will be designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell vaccination with clinically isolated syndrome and relapsing-remitting multiple sclerosis patients.
-
Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
-
Fatigue and functional deficits in multiple sclerosis (MS) patients were significantly improved during 4 weeks of inpatient rehabilitation, researchers reported
-
In a new study of patients diagnosed with multiple sclerosis (MS) after the age of 60, nearly half of relapsing patients with relapsing-remitting multiple sclerosis (RRMS) and patients with clinically isolated syndrome presented with signs of inflammation
-
Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
-
A new study showed that very active patients who received COPAXONE(R) (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (Pless than0.0001) compared to those
-
Schering AG Germany, announced today results from the subgroup analysis of the BENEFIT* study which showed that Betaferon® (interferon beta-1b) 250mcg treatment reduced the risk of developing clinically definite MS (CDMS) consistent
-
The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo
-
This study will evaluate the long-term safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
